Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$897.85 ▲ +6.09
(+0.68%)
MKT CAP: $55.72B • VOL: 161.0K
52W L $662 52W H $1,073
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$754
MEDIAN
$1,006
MEAN
$1,024
HIGH
$1,221
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ARGX TAPE
ARGX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $1,086.40 | $1,032.53 | 2025-02-14 | $817.04 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $1,131.29 | $1,059.46 | 2025-02-06 | $843.98 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $1,023.55 | $987.64 | 2025-01-29 | $861.94 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $915.81 | — | 2025-01-17 | $879.89 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $790.11 | $852.96 | 2025-01-09 | $799.09 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $1,068.44 | $933.76 | 2024-12-18 | $781.13 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $870.91 | $906.83 | 2024-12-04 | $835.00 | -4.3% | 48% | C |